Insulin receptor substrate 4 (IRS4) is a constitutive active oncogenic driver collaborating with HER2 and causing therapeutic resistance

por Ikink, Gerjon J., Hilkens, John
Publicado 2017

IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation

por Ikink, Gerjon J., Boer, Mandy, Bakker, Elvira R. M., Hilkens, John
Publicado 2016

Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance

por Ikink, Gerjon J., Boer, Mandy, Bakker, Elvira R. M., Vendel-Zwaagstra, Annabel, Klijn, Chris, ten Hoeve, Jelle, Jonkers, Jos, Wessels, Lodewyk F., Hilkens, John
Publicado 2018

RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis

por Hilkens, John, Timmer, Nikki C, Boer, Mandy, Ikink, Gerjon J, Schewe, Matthias, Sacchetti, Andrea, Koppens, Martijn A J, Song, Ji-Ying, Bakker, Elvira R M
Publicado 2017